• Z6·尊龙凯时「中国」官方网站z6尊龙

    |
    EN
    |
    EN
    EN
    • 业务咨询

      中国:

      Email: marketing@kangtya.com

      业务咨询专线:400-780-8018

      (仅限服务咨询,其他事宜请拨打川沙总部电话)

      川沙总部电话: +86 (21) 5859-1500

      海外:

      +1(626)986-9880(U.S. - West Coast)

      0044 7790 816 954 (Europe)

      Email:marketing@medicilon.com

    在线留言×
    点击切换
    Customer Center
    客户中心

    设计合成一系列用于治疗胃癌的多靶点受体酪氨酸激酶抑制剂,并进行生物学评价。其中药代动力学分析通过z6尊龙进行

    2023-07-06
    |
    访问量:

    36.jpg

    Gastric cancer is the second most lethal cancer across the world. Compounds 8f, inhibits FGFR1 signaling pathways as well as induces cell apoptosis, is a potential agent for the treatment of gastric cancer. The pharmacokinetical profile (PK) of 8f was tested in SD rats. Compound 8f showed an acceptable half-time of 3 h and displayed moderate maximum concentrations, which is enough to meet the concentration of the compound 8f to exert its efficacy in vivo. The pharmacokinetic analysis was performed by the testing service provided by Medicilon. 

    Reference:

    Xiuli Wu, et al. Design, synthesis and biological evalsuation of a series of novel pyrrolo[2,3-d]pyrimidin/pyrazolo[3,4-d]pyrimidin-4-amine derivatives as FGFRs-dominant multi-target receptor tyrosine kinase inhibitors for the treatment of gastric cancer. Bioorg Chem. 2022 Oct;127:105965. doi: 10.1016/j.bioorg.2022.105965. 


    相关新闻
    网站首页
    z6尊龙